Domenico Valerio - 18 Mar 2026 Form 3 Insider Report for ProQR Therapeutics N.V. (PRQR)

Role
Director
Signature
/s/ Pieter Erik de Ridders, Attorney-in-Fact
Issuer symbol
PRQR
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 16:08:46 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Valerio Domenico Director PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, LEIDEN, NETHERLANDS /s/ Pieter Erik de Ridders, Attorney-in-Fact 18 Mar 2026 0002117550

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRQR Ordinary Shares 420,729 18 Mar 2026 Direct
holding PRQR Ordinary Shares 304,963 18 Mar 2026 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 5,815 $4.89 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 32,164 $4.90 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 27,500 $3.30 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 14,918 $15.78 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 24,615 $9.91 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,239 $4.20 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,931 $8.01 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 22,608 $3.41 Direct F3
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 23,489 $1.98 Direct F4
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 22,128 $2.65 Direct F5
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 25,192 $2.02 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Valerio family foundation, Stichting Administratiekantoor Endavit, for which the Reporting Person is the managing director. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such shares for purposes of Section 16 of the Exchange Act, or for any other purpose.
F2 Fully vested.
F3 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F6 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney